MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.…
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
MacroGenics (NASDAQ: MGNX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 293 employees.
The shares were at 1.960 USD on 20 November 2026, up 43.1% over 52 weeks. Its 52-week range is 1.320 USD to 5.080 USD: the price is 61.4% below the high and 48.5% above the low.
Its market capitalisation is 125.26M USD.
MacroGenics reports return on equity of -134.2%, an operating margin of -48.8% and revenue down 64.8% year over year.
It holds more cash than debt, a net cash position of 252.82M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 8 March 2027.